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• Overlap between toxic effects of DAAs and toxic effects of conditioning regimens and 
symptoms of graft-versus-host disease (GVHD) in HCV-infected HCT candidates and 
recipients 
• References 
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Preface 
In recent years, management of hepatitis C virus (HCV) infection has changed 
dramatically owing to the approval of new antiviral therapies. The purpose of the American 
Society for Blood and Marrow Transplantation (ASBMT) Task Force on HCV infection in 
hematopoietic cell transplant (HCT) recipients is to provide guidance regarding diagnosis and 
management of HCV infection in donors and recipients of hematopoietic cells. 
Limited data are available on treating HCV infection in HCT recipients. A group of 
experts in infectious diseases, hepatology, and HCT worked together to compile this document 
with two goals: (1) to summarize the currently available data in the field and (2) to provide 
evidence-based and expert opinion recommendations regarding early identification and treatment 
of HCV-infected donors and recipients to minimize barriers to HCT and improve care and 
outcomes in this population. In preparing this report, the committee recognizes that, in the 
absence of data in donors and recipients of hematopoietic cells, clinicians would benefit from 
preliminary guidance while awaiting the completion of appropriate studies. 
The recommendations herein are based on synthesis of limited evidence, theoretical 
rationales, practical considerations, and author opinion. When appropriate, the level of the 
evidence and the strength of the recommendation have been rated applying the system used for 
the Hepatitis C Guidance of the American Association for the Study of Liver Disease (AASLD) 
and Infectious Disease Society of American (IDSA) (http://hcvguidelines.org) (Table 1).1 
However, for some individual recommendations, the level of the supporting evidence and 
strength of the recommendation could not be rated. 
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For this report, HCT is defined as transplant of any blood- or marrow-derived 
hematopoietic progenitor cells, regardless of whether the transplant is allogeneic or autologous 
and regardless of the cell source (i.e., bone marrow, peripheral blood, or umbilical cord blood). 
The recommendations in this document are based on data from the following sources: 
research published in the peer-reviewed literature or presented at major national and international 
scientific conferences; safety warnings from the US Food and Drug Administration (FDA), or 
other regulatory agencies or from manufacturers; drug interaction data; and prescribing 
information for FDA-approved products. Literature searches were conducted using medical 
subject headings and free text terms combined to maximize retrieval of relevant citations from 
the PubMed, Scopus, EMBASE, and Web of Science databases; search terms included “HCV 
and Bone Marrow Cell Transplantation” and “HCV and Hematopoietic Stem Cell 
Transplantation”. Only articles published in English from 1990 to the present were considered 
for inclusion. 
The ASBMT plans to review these recommendations and update them to include 
advances in the published evidence. 
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Executive summary 
For more than a decade, the mainstay of treatment for HCV infection was a combination 
regimen of pegylated interferon and ribavirin, but this regimen was associated with a poor rate of 
sustained virologic response (SVR) and poor tolerability, especially in cancer patients and HCT 
recipients.2,3 Furthermore, almost 30% of infected HCT recipients could not be treated with 
pegylated interferon and ribavirin because of contraindications to the treatment combination.3 
The management of HCV infection in the general population has recently changed as a 
result of FDA approval of several direct-acting antiviral agents (DAAs), which have rendered 
interferon-containing regimens obsolete for almost all HCV genotypes.  
This report, developed by the ASBMT, is specifically devoted to diagnosis and 
management of HCV infection in donors and HCT candidates/recipients. There are few data 
which answer important clinical questions for such donors or recipients. The on line document 
AASLD-IDSA “Recommendations for Testing, Managing, and Treating Hepatitis C” 
(http://www.hcvguidelines.org), which are updated regularly throughout the year, were used as a 
resource in the development of this report, but had no specific recommendations for these 
populations. Thus, this document was developed to provide expert opinion for clinicians who 
must make management decisions while awaiting adequately powered trials dealing with donors 
and HCT recipients. 
Evidence is summarized, and where possible, recommendations are provided. This report 
replaces the 2009 ASBMT-IDSA guideline. 4 Several topics are new or expanded from that 
document (table 2).  
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Natural history of HCV infection in HCT recipients 
G. B. McDonald, M. De Lima 
 
Recommendations 
• In all HCT survivors with active HCV infection, cofactors that can lead to fibrosis should be 
addressed. Counseling the patients to avoid excessive weight gain, ethanol and medications 
or herbal supplements that are hepatotoxic; treatment of other causes of liver disease (non-
alcoholic fatty liver disease, hepatitis B virus, HIV, and extrahepatic obstruction) (class I, 
level C); and mobilization of excess iron (class II, level C). 
• All HCV-infected long-term HCT survivors should be evaluated for progression of liver 
disease every 6 to 12 months with a hepatic function panel, complete blood cell count, and 
evaluation of prothrombin time/international normalized ratio (class I, level C). If fibrosis is 
suspected in long-term HCT survivors, noninvasive tests such as serologic panels and 
transient elastography can be used to evaluate for the presence of advanced fibrosis (Scoring 
System for Histological Stage Metavir score ≥F3) and cirrhosis (Metavir score F4). 
• HCV-infected HCT recipients should be vaccinated against hepatitis A virus and hepatitis B 
virus following HCT immunization protocols.4 
• Donors and HCT candidates with HCV infection should be counseled to use appropriate 
precautions to prevent transmission of HCV to others (class I, level C). 
• For HCV-infected HCT long-term survivors with advanced fibrosis (Metavir score ≥F3), 
surveillance for hepatocellular carcinoma (HCC) with ultrasonography every 6 months is 
recommended (class I, level C). For patients with cirrhosis, endoscopic surveillance for 
esophageal varices is recommended (class I, level A). 
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• HCT recipients who develop end-stage liver disease can be considered for liver transplant; 
in rare cases, a living donor liver transplant from the original hematopoietic cell donor may 
be feasible (class I, level C). 
 
Evidence summary 
Course of HCV infection to 1 year after HCT 
HCV infection has hepatic and extrahepatic manifestations. Hepatic manifestations in 
HCT recipients in addition to those seen in immunologically normal hosts include (1) an 
increased risk of fatal sinusoidal obstruction syndrome (previously known as veno-occlusive 
disease) among patients with chronic HCV infection who receive sinusoidal endothelial cell 
toxins (e.g., cyclophosphamide, etoposide, melphalan, thiotepa, total body irradiation ≥12 Gy) as 
part of conditioning therapy;5 (2) hepatic inflammation occurring 3-6 months after HCT, 
coincident with immune reconstitution and discontinuation of immunosuppressive drugs;5 (3) 
liver decompensation among patients who had cirrhosis at the time of transplant;6,7 and (4) 
rarely, fatal fibrosing cholestatic hepatitis C before day 100 in patients receiving mycophenolate 
mofetil.8 Fibrosing cholestatic hepatitis is an aggressive form of viral hepatitis caused by either 
hepatitis B virus or HCV that causes rapid clinical deterioration, characterized histologically by 
extensive fibroblastic portal-to-portal bridging, ductular proliferation, cholestasis, high intra-
hepatocyte viral load, and inflammation.8 Extrahepatic manifestations of HCV infection after 
HCT have been suggested by epidemiologic studies and include greater 1- to 2-year non-relapse-
related mortality than in HCV-negative controls, including an excess of deaths related to 
bacterial infections.6,7 It is not clear if the higher mortality is due to HCV per se, the presence of 
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undetected hepatic fibrosis and portal hypertension, or chronic viral co-infections (such as 
hepatitis B virus infection or HIV infection) at the time of transplant. 
 
Course of HCV infection between 1 and 10 years after HCT 
Coincident with immune reconstitution after HCT, serum alanine aminotransferase 
(ALT) levels wax and wane in most HCV-infected patients. The course of this chronic hepatitis 
is usually uncomplicated for 10 years after HCT, but rarely, patients may progress to cirrhosis. 
Serum aminotransferase elevations can be seen in 57% of HCV-infected patients between 5 and 
10 years after HCT.5 In several series, no excess mortality was noted in HCV-infected patients 
up to 10 years after HCT.5,9,10 In some patients, however, the duration of HCV infection before 
HCT can only be estimated, and the extent of fibrosis is unknown at the time of HCT; such 
patients may experience progressive liver disease that only becomes apparent following HCT.6,7 
 
Course of HCV infection 10 to 40 years after HCT 
Chronic HCV is the leading cause of cirrhosis after HCT, and the time to cirrhosis is 
shorter in patients with chronic HCV infection who undergo HCT than in patients with chronic 
HCV infection who do not undergo HCT.11,12 About one-third of HCV-infected 40-year 
survivors of HCT develop end-stage liver disease (cirrhosis, HCC, or disease requiring liver 
transplant).  
HCT recipients who develop end-stage liver disease can be considered for liver 
transplant; living donor liver transplant from the original hematopoietic cell donor has been 
described.13,14 
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Knowledge gaps 
• What is the natural history of HCV in HCT in the era of current immunosuppressive 
regimens? 
• What are the predictors of liver disease progression in HCT recipients? 
• Do effective antiviral drugs alter the course of HCV-related fibrosing cholestatic hepatitis, 
hepatic fibrosis, and cirrhosis in HCV-infected survivors of HCT? 
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HCV screening in donors of hematopoietic stem cells, HCT candidates and long-term 
survivors 
S. P. Hammond, J. R. Wingard 
 
Recommendations 
• All hematopoietic cell donors should be screened for HCV within 30 days before cell harvest 
with FDA-approved HCV antibody (anti-HCV) and RNA testing in accordance with the 
Foundation for the Accreditation of Cellular Therapies (FACT) standards and FDA guidance 
(class I, level C). 
• All HCT candidates should be screened for HCV with FDA-approved anti-HCV testing 
(class I, level C). 
• All long-term survivors of HCT should be screened for HCV infection based on the current 
recommendations for screening in non HCT recipients, with special attention to those with 
epidemiologic risk factors including those transplanted in the era before routine donor and 
blood product screening (class I, level C).  
 
Evidence summary 
In the general US population, risk-based screening for HCV infection with anti-HCV 
testing (with reflex HCV RNA testing for individuals with positive results) is recommended by 
the Centers for Disease Control and Prevention,15 US Preventive Services Task Force,16 and 
AASLD, IDSA, and International Antiviral Society–USA.1 Individuals considered at high risk 
include not only intravenous drug use but also individuals born between 1945 and 1965.15  
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Transmission of HCV from HCV-infected bone marrow donors to uninfected recipients 
was first documented in the early 1990s.17 FACT has issued standards for US centers performing 
HCT that include HCV screening of allogeneic donors within 30 days before stem cell harvest 
using tests required by applicable laws and regulations.18 The FDA has issued guidelines 
recommending that such donors be screened with FDA-licensed antibody and nucleic acid 
tests.19 A positive test result for anti-HCV (using third generation tests) in the setting of 
undetectable serum HCV RNA indicates past infection (resolved spontaneously or 
therapeutically), acute HCV infection during a period of low-level viremia, or a false-positive 
test result.1,20  
False-positive anti-HCV tests are more common with earlier generation testing, 
especially if confirmation with the recombinant immunoblot assay (RIBA) was not included in 
the method. In such a case, the HCV-treating providers should retest the donor for anti-HCV and 
HCV RNA to exclude the presence of active infection and seek guidance from an infectious 
disease or hepatology expert. 
The presence of serum HCV RNA indicates current and active infection. If the viremia 
persists for more than 6 months post exposure, the infection is considered chronic and is not 
likely to resolve spontaneously. 
FACT and FDA guidance on HCT donor screening does not extend to HCT candidates 
and recipients. Overall, HCV screening in HCT candidates establishes a pretransplant baseline 
and identifies patients who might benefit from HCV treatment after transplant. There is usually 
insufficient time to complete a course of HCV therapy prior to HCT.  
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Chronic HCV can be associated with false-negative anti-HCV test results in 
immunosuppressed patients,20 including HCT recipients.21 Such patients have a positive serum 
HCV PCR test. 
In a prospective study in allogeneic HCT recipients from 15 European transplant centers, 
data on pretransplant HCV-RNA were available for 182 patients and 11 were found to have 
viremia including 6 anti-HCV negative patients.21 In HCT candidates and recipients, screening 
with HCV RNA testing in addition to anti HCV serologic testing is advocated by many experts 
(class IIb, level C). In one study, 13% of HCV-infected patients with a positive anti-HCV test 
result before HCT had a negative anti-HCV test result after HCT.22  
 
Knowledge gap 
• How frequently are HCT candidates or HCV recipients seronegative for HCV with third 
generation tests despite serum nucleic acid evidence of active infection? 
• What is the most cost effective algorithm for screening HCT candidates and recipients?  
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Impact of HCV infection on eligibility to donate hematopoietic stem cells or undergo HCT 
H. A. Torres, J. R. Wingard 
 
Recommendations 
• HCV infection in donors or potential HCT recipients should not be an absolute 
contraindication for HCT (class I, level C) (See Table 3). 
• The risk of HCV transmission is extremely low when seronegative and HCV RNA negative 
HCT candidates receive HCT from donors of hematopoietic stem cells with positive anti-
HCV and undetectable HCV RNA (class I, level C). 
• HCV-infected donors should be assessed for advanced chronic liver disease, and other 
extrahepatic manifestations of HCV to recommend an optimal management of their disease 
(class I, level C). 
• HCV infected donors should be screened for other co-infections (e.g., HIV). An HIV-HCV 
coinfected individual should not be considered as donors for HIV seronegative recipients, 
according to standard HCT guidelines.4 
• HCV-infected HCT candidates requiring HCT and for whom there is no alternative donor 
can proceed with HCT from a donor also infected with HCV provided that the recipient has 
full understanding of the potential consequences given the viral characteristics of the donors’ 
HCV infections (class IIa, level C).  
• If the donor is HCV RNA positive and transplantation to an HCV infected or uninfected 
recipient is considered, the donor should start antiviral therapy immediately with the goal of 
reducing the infectious potential of the donor, ideally attaining undetectable plasma HCV 
RNA in the donor prior to stem cell harvest (Class I Level C). 
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• Selection of HCV-infected candidates for HCT should be based on the extent of liver fibrosis 
and degree of portal hypertension (class I, level C). 
 
Evidence summary 
Donors with positive HCV screening test results 
As recommended for the general population,1 donors (or HCT recipients) found to have 
positive results for anti-HCV and negative results for HCV RNA by polymerase chain reaction 
using an FDA-approved sensitive HCV RNA test should be informed that they do not have 
evidence of current (active) HCV infection. Repeat HCV RNA testing at a later date (e.g., 1-2 
months) is typically unnecessary but can be performed when there is strong suspicion of acute 
infection or in patients with ongoing risk factors for HCV infection.1 
Up to 100% of infected donors transmit HCV to uninfected HCT recipients.17 If no 
alternative donor is available and if time does not permit treatment of the infected donor to 
eliminate HCV from the infusion product, the use of HCV-infected hematopoietic cells for an 
HCV-uninfected recipient is not contraindicated. New DAAs could potentially provide a 
virologic cure after HCT in the majority of patients and may halt liver disease progression in 
HCT survivors. The risk of dying from the underlying hematologic malignancy without the 
transplant outweighs the risk of acquiring potentially curable HCV. However, the donor should 
be assessed for advanced chronic liver disease per current HCV guidance,1 as well as 
extrahepatic manifestations of HCV (e.g., lymphoproliferative diseases), and co-infections (e.g., 
HIV) that might contraindicate donation (class I, level C).4   
The risk of transmission of HCV was decreased to nearly zero if HCV RNA was 
undetectable at the time of hematopoietic cell donation.17 In viremic donors, viral clearance with 
guide.medlive.cn
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
16 
 
DAAs prior to cell harvest may be attempted if feasible to reduce the risk of HCV transmission, 
as most donors will attain undetectable HCV PCR within 4 weeks of starting currently available 
DAA agents.4,23,24 The timing of HCV therapy is further discussed in the section When to treat 
HCV infection in donors, autologous or allogeneic HCT candidates and recipients. 
 
HCT candidates with positive HCV screening test results 
Similar to what is recommended for donors, HCT candidates with positive test results for 
anti-HCV in the setting of undetectable HCV RNA should be evaluated to exclude acute 
infection by repeating HCV RNA. HCV-infected HCT candidates requiring HCT and for whom 
there is no alternative donor can proceed with HCT from a donor also infected with HCV, 
provided that the recipient has full understanding of the potential consequences (class IIa, level 
C).5 The potential consequences include infections with different genotypes (e.g., genotype 3) or 
resistance-associated variants (such as NS5A variants) potentially associated with a higher rate of 
virologic failure. Treatment recommendations in HCT candidates are further discussed in the 
section When to treat HCV infection in donors, autologous or allogeneic HCT candidates and 
recipients. 
All individuals (donors and recipients) with HCV infection should be referred to a 
practitioner able to provide comprehensive management of HCV.1 
 
Knowledge gaps 
• Studies are needed to determine the magnitude of risk for HCV transmission when HCV 
infected donors have achieved undetectable HCV RNA but have not completed their 
recommended treatment course. 
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Monitoring HCV in HCT recipients with chronic HCV infection 
H. A. Torres, M. De Lima 
 
Recommendations 
• In HCT recipients with chronic HCV infection, ALT level should be evaluated at entry into 
care, 2 to 8 weeks after completion of the conditioning regimen, every 2 to 8 weeks during 
maintenance chemotherapy or immunosuppressive treatment, and every 3 to 6 months 
thereafter (class II, level C) 
• In HCT recipients with chronic HCV infection, routine monitoring of HCV RNA is not 
recommended. However, viral load should be considered for patients who have an 
unexplained elevation of ALT (class II, level C). HCV RNA should be measured in all 
patients at entry into care, and monitoring of viral load should be performed in patients 
receiving HCV treatment according to the AASLD-IDSA HCV guidance 
(http://www.hcvguidelines.org/) (class I, level C).  
 
Evidence summary 
Acute exacerbation of chronic HCV infection, indicated by a significant elevation of 
serum aminotransferase levels over the baseline level in the absence of other potential causes of 
acute hepatitis, can occur in both immunocompetent 25 and immunocompromised cancer 
patients.26 However, there are no standard definitions for this phenomenon. In a retrospective 
study of 308 patients with cancer and chronic HCV infection, 11% were identified as having 
acute exacerbation of chronic HCV infection, defined as a threefold or greater increase in serum 
ALT level from baseline in the absence of (1) infiltration of the liver by cancer, (2) use of 
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hepatotoxic medications, (3) blood transfusion within 1 month of elevation of ALT level, or (4) 
other systemic infections affecting the liver (including hepatitis A virus, hepatitis B virus, 
cytomegalovirus, adenovirus, herpes simplex virus, varicella zoster virus, and HIV infections).26 
In that study, acute exacerbation (significant ALT elevation) of HCV infection during 
chemotherapy prompted clinicians to discontinue chemotherapy in nearly half of affected 
patients.26 
Enhanced HCV replication (also known as HCV reactivation26) has been defined as an 
increase in HCV RNA viral load of at least 1 log10 IU/mL over baseline following chemotherapy 
or immunosuppressive therapy26 as chronically infected patients have stable HCV RNA levels 
that may vary by approximately 0.5 log10 IU/ml.27 The increased replication of HCV appears to 
be associated with a more indolent course than hepatitis B virus reactivation;28 there have been 
only few reports of deaths associated with increased HCV replication.8,29 Regrettably, the 
published data on simultaneous changes in ALT levels and HCV viral load are limited and not 
sufficient for examination of whether a correlation exists between enhanced viral replication and 
hepatocellular injury,26 as has been described for patients with chemotherapy-induced hepatitis B 
virus reactivation.  
Little is known about acute exacerbation of HCV infection in HCT recipients, with 
emerging data following autologous and allogeneic HCT recently presented.22,30 However, such 
studies should be considered preliminary as most were retrospective analyses of small numbers 
of patients. In one prospective study, aspartate aminotransferase (AST) levels were compared 
between HCV-infected and HCV-negative HCT recipients.5 A severe acute flare of hepatitis 
(AST > 10 times the upper limit of normal) developed in 11 of 36 (31%) HCV-infected patients 
who survived at least 1 year after HCT but only 6 of 115 (5%) HCV-negative patients 
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(P<0.0001). Data on HCV RNA were not presented; thus, it was not possible to determine 
whether increase in AST level in patients receiving chemotherapy resulted from co-infections, 
drugs, or enhanced HCV replication in the setting of immunosuppression.  
Patients with significant ALT elevations (e.g., threefold or greater increase from the 
upper limit of normal) should be carefully evaluated for signs and symptoms of liver 
insufficiency and for alternative causes of liver injury. HCV-treating physicians should 
participate in the diagnostic workup of acute exacerbation of HCV to exclude other potential 
explanations for ALT increase (e.g., infiltration of the liver by cancer, hepatotoxic medications, 
blood transfusion within 1 month, the hepatitic presentation of liver GVHD, or other systemic 
infections affecting the liver). 
 
Knowledge gaps 
• Prospective studies are needed to determine the incidence, clinical implications and outcome 
of acute exacerbation of chronic HCV infection in HCT recipients. 
• What is the best strategy for monitor HCV infection around the time of HCT? 
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Fibrosis assessment in HCV-infected HCT candidates and recipients 
M. Gambarin-Gelwan, M. S. Friedman 
 
Recommendations 
• All HCV-infected HCT candidates should undergo assessment of the stage of liver fibrosis 
and the presence of cirrhosis (class I, level C). 
• The presence of cirrhosis may affect duration and type of HCV therapy and will identify 
patients who need to be screened for HCC and the presence of esophageal varices (class I, 
level C).  
• The decision to perform a liver biopsy should be made only after careful consideration of the 
risks and benefits of the procedure (class I, level B). 
• Serologic marker panels for detection of fibrosis have not been studied in HCV-infected 
HCT candidates, and their use is not recommended (class IIb, level C). 
• Ultrasound-based vibration-controlled transient elastography (FibroScan VCTE) have not 
been studied in HCT recipients and thus results should be interpreted with caution (class II, 
level C). 
  
Evidence summary 
All HCV-infected HCT candidates should undergo assessment of the stage of liver 
fibrosis and the presence of cirrhosis (class I, level C). The presence of advanced fibrosis 
(Metavir ≥F3) or cirrhosis (Metavir F4) may have a significant impact on HCT eligibility, the 
choice of conditioning regimen, HCV therapy, and risk of HCC.  
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Liver biopsy 
Liver biopsy has been the gold standard for histopathological assessment of fibrosis in 
patients with chronic HCV infection, particularly when the stage of fibrosis and presence or 
absence of cirrhosis may guide subsequent management. However, liver biopsy is an imperfect 
gold standard because it is associated with sampling limitations and error, it is invasive, and it 
carries a risk of complications. Individuals with hematologic malignancies requiring HCT may 
be at particular risk for complications31 and often require a transjugular approach because of 
severe thrombocytopenia.32 The decision to perform a liver biopsy should be made only after 
careful consideration of the risks and benefits of the procedure (class I, level B).33 
 
Serologic marker panels for detection of fibrosis  
Tests for serologic markers of fibrosis have become widely available in the past several 
years and are used extensively in patients with chronic HCV infection. The AST to platelets ratio 
(APRI), FIB-4 are easy to calculate using data available on routine laboratory testing. Four 
commercial serum marker panels have been validated in the general population of patients with 
chronic HCV infection: FibroTest/FibroSure (LabCorp), Hepascore (Quest Diagnostics), 
FibroSpect (Prometheus Corp), and the European Liver Fibrosis Study Group panel (not 
available in the US). No panel has yet emerged as standard of care or is FDA approved; 
however, all four panels have demonstrated accuracy in distinguishing patients with significant 
fibrosis (Metavir score F2-F4) from those without significant fibrosis (Metavir score F0 or F1).34 
Because individual markers included in these panels include aminotransferases, platelets, 
coagulation parameters, gamma-glutamyl transferase, total bilirubin, haptoglobin, gamma 
globulins, etc., the results might be unreliable in HCT candidates and recipients because of 
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cytopenias, ongoing systemic inflammation, drug-related liver damage, and infection. These 
panels have not been studied in candidates for HCT, or in HCT recipients and their use is not 
recommended in either population. 
 
Vibration-controlled transient elastography 
Ultrasound-based elastography in the form of FibroScan VCTE was approved by the 
FDA in April 2013. This procedure has been endorsed by the AASLD “to be used by clinicians 
providing care for patients with liver disease to evaluate liver fibrosis at the point of care”.35 
VCTE is quick, is done at the time of the clinic visit, is noninvasive, has good reproducibility, is 
relatively inexpensive, and provides information about a large area of the liver. VCTE has been 
extensively studied in patients with chronic HCV infection. In a recent US multicenter study, it 
demonstrated a positive predictive value of 75.6% to 80.8% and a negative predictive value of 
55.0% to 84.7% for diagnosis of significant fibrosis (F≥2) and an estimated positive predictive 
value of 41.6% to 60.4% and negative predictive value of 95.6% to 97.6% for diagnosis of 
cirrhosis.36  
VCTE would plausibly be useful for assessment of advanced fibrosis, particularly to rule 
out cirrhosis in HCT candidates and recipients although these patient populations have not been 
extensively studied.37,38 
 
Knowledge gaps 
• Reliability of serologic markers of fibrosis and FibroScan VCTE in predicting the presence 
of advanced fibrosis and cirrhosis in HCT candidates and recipients. 
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• Effect of leukemic infiltration of hepatic sinusoids, lymphoma of the liver or extramedullary 
hematopoiesis with sinusoidal fibrosis on the accuracy of VCTE. 
• Role of VCTE as a predictor of hepatotoxicity in HCT recipients. 
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When to treat HCV infection in donors, autologous or allogeneic HCT candidates and HCT 
survivors 
M. Gambarin-Gelwan, S. Giralt, G. B. McDonald 
 
Recommendations 
• HCV-infected donors should be evaluated for HCV therapy and treated before cell harvest to 
prevent transmission of HCV to uninfected recipients, if possible (class I, level C). 
• All HCT candidates with HCV infection should be evaluated for HCV therapy before the 
start of conditioning therapy; after transplant, HCV-infected survivors should also be 
evaluated for therapy (class I, level B).  
• When possible, HCV-infected HCT candidates should be started on therapy and should 
complete therapy for HCV before transplant (class IIa, level C). 
• After HCT, the following patients should be treated for HCV without delay: HCV-infected 
patients who develop fibrosing cholestatic hepatitis C, patients with cirrhosis whose 
condition is deteriorating, and patients who underwent HCT for HCV-related 
lymphoproliferative disorders (class I, level C).  
• After HCT, treatment for HCV can be deferred until after immune reconstitution for patients 
not meeting the criteria above (class I, level C). 
• All HCV-infected long-term survivors of HCT should be offered antiviral therapy (class I, 
level C). 
• HCV therapy should be undertaken only with the intention of completion of the full course of 
therapy as defined in the AASLD-IDSA HCV Guidance (http://www.hcvguidelines.org/). 
Treatment interruption is not recommended (class I, level C). 
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• Interferon-based regimens should be avoided in donors, and HCT candidates/recipients with 
HCV infection because of their suboptimal efficacy and safety (class I, level B). 
• HCV therapy should be undertaken by providers experienced in management of HCV in 
HCT recipients in close collaboration with transplant teams (class I, level B). 
 
Evidence summary 
Treatment of HCV-infected donors before HCT 
Several case reports have described successful prevention of HCV transmission through 
treatment of HCV-infected donors prior to cell harvest.5,24,39,40 When there are oncologic 
imperatives for moving quickly to transplant, DAAs should be able to clear extrahepatic HCV 
from donors more quickly than interferon and ribavirin can without significant toxic effects on 
the donor marrow. Once initiated, a full course of antiviral therapy should be completed in 
donors based on the current treatment recommendations for individuals with HCV infection.1  
The risk of HCV transmission at various time points during HCV therapy has not been 
studied. Plausibly the risk of transmission should be sharply reduced if serum HCV RNA levels 
are below the level of detection for the assay. 
 
Treatment of HCV-infected candidates before HCT and recipients after HCT 
Data are lacking regarding treatment of HCV-infected HCT candidates. DAA therapy 
before HCT should be considered.  
Prompt treatment of HCV infection after transplant is urgent for three groups: patients 
with fibrosing cholestatic hepatitis C,8 patients with cirrhosis whose condition is deteriorating,41 
and patients who underwent HCT for HCV-related lymphoproliferative disorders.22,42 It is not 
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known, however, whether the efficacy of DAA therapy is affected by dysfunctional immunity 
following therapy for cancer. It is also not known whether eliminating HCV before HCT 
improves the outcome of transplant by, for example, reducing the risks of post-HCT fatal 
sinusoidal obstruction syndrome, liver decompensation, fibrosing cholestatic hepatitis, or 
recurrent lymphoma.43,44 Once HCV therapy is started in either HCT candidates or recipients, 
treatment interruption is not recommended, as it is associated with increased risk of treatment 
failure.2  
The alternative to pre-HCT therapy for HCV is to treat after HCT using DAAs following 
immune reconstitution.22 Although published data are limited on outcomes of DAA therapy in 
HCT recipients, SVR rates of 70% to 96% have been observed in patients who received DAAs 
during immunosuppressive therapy after liver transplant.43,44 
A preliminary observational study suggests that interferon-sparing regimens are well 
tolerated and effective in 10 HCT recipients and have potential to improve patient outcomes.22  
Combination DAA therapy appears to be safe and effective in HCV-infected allogeneic and 
autologous HCT recipients after a follow-up period of 6 months after transplant.22 Some experts 
advocate waiting for 6 months after the transplant allowing tapering of immunosuppression 
agents and graft-versus-host disease (GVHD) prophylaxis, which might result in higher SVR 
rates and reduction of drug-drug interactions.  
Flare of GVHD that occurred after tapering immunosuppressive therapy could be 
confused for HCV exacerbation and/or medication toxicity in those receiving antivirals. Some 
clinicians may still choose to defer DAA therapy until immunosuppressive treatment has 
been discontinued to avoid drug-drug interactions. 
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Interferon-based regimens should be avoided in donors and HCT candidates with HCV 
infection because of their suboptimal efficacy and safety (class I, level B). Data are not available 
regarding the impact of treatment regimens consisting of ribavirin plus DAA in HCV-infected 
HCT recipients. 
 
Treatment of HCV-infected long-term HCT survivors 
About one-third of HCV-infected long-term HCT survivors develop end-stage liver 
disease or HCC.11,12 Thus, al HCV-infected long-term HCT survivors should be offered DAA 
therapy. The rationale for universal treatment of infected survivors is that it can prevent 
transmission of HCV, delay the development of cirrhosis and reduce long-term consequences of 
chronic HCV infection, including development of HCC, extrahepatic manifestations of HCV, 
and possible need for liver transplantation.  
 
Knowledge gaps 
• Should all HCV-infected donors and HCT candidates be treated with antivirals before HCT? 
• What is the optimal timing of antiviral therapy for HCT candidates? 
• How effective and safe are DAAs given to HCT candidates or recipients? 
• What is the effect of virological cure of HCV on the risk of sinusoidal obstruction syndrome 
and other liver-related complications of HCT in HCV-infected individuals? 
• Does antiviral therapy prevent post-HCT liver disease progression and relapse of HCV-
associated non-Hodgkin lymphoma? 
• Does recovery of a full immunologic repertoire after HCT affect the efficacy of antiviral 
treatment? 
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Role of DAA combinations in HCV-infected HCT recipients 
P. P. Chong, M. S. Friedman, H. Masur 
 
Recommendations 
Recommendations by HCV genotype as of July 2015 
• For infection with genotype 1a, 1b, or 4 HCV, treatment with one of the following three 
DAA combinations is recommended:  
(1) Daily fixed-dose combination of ledipasvir and sofosbuvir 
(2) Twice-daily fixed-dose combination of ombitasvir, paritaprevir, ritonavir, and dasabuvir 
with or without ribavirin 
(3) Daily sofosbuvir plus simeprevir.   
The choice of regimen should be individualized on the basis of patient-specific data, 
including potential drug interactions. 
• For infection with genotypes 2, 3, or 5 HCV, the preferred regimen is sofosbuvir plus weight-
based ribavirin. 
• Monotherapy with a DAA is not recommended for any patient with HCV infection (class III, 
level A). 
 
Treatment considerations in specific patient populations 
• HCT recipients often receive multiple drugs that could have pharmacologic interactions with 
DAAs or toxic effects that overlap with those of DAAs. Treating physicians should be 
mindful of potential drug interactions and/or side effects although not extensively studied in 
HCT recipients. 
guide.medlive.cn
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
29 
 
• In patients with mild (creatinine clearance 60-89 mL/min) to moderate (creatinine clearance 
30-59 mL/min) renal impairment, no dosage adjustment is required for sofosbuvir plus 
simeprevir, ledipasvir plus sofosbuvir, or ombitasvir, paritaprevir, ritonavir and dasabuvir 
(class I, level A). The total daily dose of ribavirin should be reduced for patients with creatinine 
clearance less than or equal to 50 mL/min.45 
• In patients with severe renal impairment (creatinine clearance 15-29 mL/min) or with end-
stage renal disease, safety and efficacy data for DAAs are not available; treatment can be 
contemplated after consultation with an expert (class IIb, level C) or as new data in this 
patient population becomes available.  If ribavirin used, dose should be reduced.45 
• Patients co-infected with HIV and HCV should be treated like HCV-monoinfected patients, 
except that interactions with antiretroviral medications must be recognized and managed 
(class I, level B). 
 
Evidence summary 
DAAs are oral agents that target various HCV-encoded proteins vital to the replication of 
the virus. When used in combination, DAAs are capable of curing HCV infection; DAAs have 
demonstrated excellent rates of SVR and favorable safety profiles in multiple phase 3 clinical 
trials.46-51 
Unfortunately, the efficacy and safety of DAAs in HCV-infected HCT recipients have 
not been extensively studied or documented. The recommendations above are extrapolated from 
studies in other patient populations. The optimal therapy for HCV is evolving rapidly and will 
continue to evolve as multiple new drugs are approved and as more studies are reported. The 
recommendations above should be compared to the online AASLD-IDSA HCV guidance for the 
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management of HCV infection, which are updated frequently as new data emerge 
(http://www.hcvguidelines.org/news/hcv-guidance). 
The choice of DAA regimen and duration of DAA treatment for HCV-infected HCT 
recipients should be informed by prior treatment experience, HCV genotype, and the degree of 
fibrosis. 
The combination of sofosbuvir and daclatasvir is approved by the FDA for use in patients 
with genotype 3 HCV infection in the US.52  
 
Knowledge gaps 
• Efficacy and safety of various DAA regimens in HCT recipients. 
• Optimal duration of DAA regimens in HCT recipients. 
 
  
guide.medlive.cn
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
31 
 
Drug-drug interactions in HCV-infected HCT candidates and recipients receiving DAAs 
and conditioning regimens or immunosuppressive agents 
P. J. Kiel 
 
Recommendations 
• Physicians should frequently assess for drug-drug interactions in HCV-infected HCT 
recipients (class I, level C). 
• HCT candidates should not receive DAAs concomitantly with the chemotherapy preparative 
regimen if potential for drug-drug interactions exists (class I, level C). 
• In patients receiving tacrolimus concomitantly with paritaprevir and ritonavir, increased 
therapeutic drug monitoring and a 50% to 75% decrease of the tacrolimus dose may be 
required (class IIb, level B).  
• In patients receiving cyclosporine concomitantly with paritaprevir and ritonavir, increased 
therapeutic drug monitoring and a 35% to 50% decrease of the cyclosporine dose may be 
required (class IIb, level B). Sofosbuvir should not be administered concomitantly with 
cyclosporine. 
• In patients receiving sirolimus concomitantly with paritaprevir and ritonavir, increased 
therapeutic drug monitoring and a decrease of up to 90% of the sirolimus dose may be 
required (class IIb, level C). 
 
Evidence summary 
The introduction of novel antiviral agents in the treatment of HCV has not eliminated the 
risk of drug interactions. Physicians should frequently assess for drug-drug interactions in HCV-
guide.medlive.cn
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
32 
 
infected HCT recipients. Many interactions may not be adequately documented but rather may 
have to be inferred on the basis of the isoenzymes responsible for drug metabolism. Current 
databases (e.g., http://www.hep-druginteractions.org) should be consulted along with the product 
prescribing information to ensure the safety of concomitantly prescribed medications such as 
acid reducers, antidepressants, antihypertensives, phosphodiesterase inhibitors, novel oral 
anticoagulants, macrolide antibiotics, triazoles and HMG Co-A inhibitors.1 However, these 
databases lack documentation of potential interactions between DAAs, commonly prescribed 
immunosuppressive agents, and chemotherapy. The pharmacology of DAAs and potential drug-
drug interactions between DAAs and chemotherapy or immunosuppressive agents used in 
patients undergoing HCT are summarized in Table 4.53-58 
Drug-drug interactions can be pharmacokinetic, resulting in changes in drug 
concentrations, or pharmacodynamic, resulting in additive, synergistic, or antagonistic effects on 
efficacy or toxicity. Metabolism by CYP450 enzyme, specifically the CYP3A4 isoform, is the 
major metabolic pathway of approved HCV therapies, including DAAs. Membrane transporters 
are also implicated in clinically relevant drug-drug interactions and may include P-glycoprotein, 
organic anion transporting polypeptides, and the ATP-binding cassette subfamily G member 2. 
Membrane transporters and the CYP isoenzymes can be induced or inhibited. 
The pharmacologic targets of the novel DAAs include NS3/NS4A protease inhibitors, 
NS5A inhibitors, and NS5B polymerase inhibitors. The protease inhibitors (paritaprevir, 
simeprevir, telaprevir and boceprevir) prevent the NS3 viral protease from cleaving the enzymes 
responsible for viral replication. All five agents undergo CYP3A4 metabolism and are affected 
by inducers (i.e., phenytoin, rifampin, carbamazepine, and phenobarbital) and inhibitors (i.e., 
posaconazole and voriconazole).18,54-58 
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The protease inhibitors may also increase serum concentrations of chemotherapy or 
immunosuppressive agents commonly used for HCT that are substrates of CYP3A4, including 
cyclophosphamide, etoposide, tacrolimus, cyclosporine, and sirolimus. Paritaprevir is 
administered concomitantly with ritonavir, a potent CYP3A4 inhibitor, as a “boosting” agent and 
will also interfere with other CYP3A4 and CYP2D6 metabolized medications. Thiotepa is an 
inhibitor of CYP2B6 and has no interactions with DAAs. 
The NS5A inhibitors (daclatasvir, ledipasvir, and ombitasvir) inhibit NS5A viral RNA 
replication and virion assembly. Daclatasvir is metabolized via CYP3A4, while ledipasvir and 
ombitasvir undergo oxidative metabolism.52,55,58 Ledipasvir is an inhibitor and a substrate of 
intestinal P-gp; inducers of P-gp (i.e., St. John’s Wort, rifabutin, phenobarbital) that are co-
administered may lead to reduced plasma concentrations and therapeutic effects of ledipasvir.58 
The polymerase inhibitor sofosbuvir is renally eliminated, while dasabuvir is metabolized 
via CYP2C8 (major pathway), 3A4, and 2D6. 55,55 Sofosbuvir is a substrate of intestinal P-gp and 
inducers of P-gp (i.e., St. John’s Wort, rifabutin, phenobarbital) that are co-administered may 
lead to reduced plasma concentrations and therapeutic effects of sofosbuvir.58 
Immunosuppression with cyclosporine, tacrolimus, and sirolimus is common following 
HCT. Cyclosporine has been observed to increase sofosbuvir AUC by 353%.59 Simeprevir can 
increase cyclosporine and tacrolimus AUC by 19% and 17%, respectively.60 Telaprevir increases 
the dose-normalized exposure AUC0-∞ values of cyclosporine and tacrolimus approximately 4-
fold and 70-fold, respectively.61 The mean half-life of cyclosporine was increased from 12 hours 
to 42.1 hours, and the mean half-life of tacrolimus was increased from 40.7 hours to 195 hours. 
Boceprevir increases the AUC0-∞ values of cyclosporine and tacrolimus approximately 3-fold 
and 17-fold, respectively.62 Experience with dosing of immunosuppressive agents following liver 
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transplant concomitantly with telaprevir or boceprevir plus interferon and ribavirin suggests an 
empiric dose reduction of approximately 75% for tacrolimus and 35% for cyclosporine.63,64 
Telaprevir and boceprevir are no longer available in the US. Sirolimus plasma concentrations 
with use of DAA have not been prospectively evaluated, but case reports in patients with liver 
transplant would suggest a 90% dose decrease.64 
When a calcineurin inhibitor or sirolimus is used with a protease inhibitor, it is 
reasonable to empirically reduce the dose of the immunosuppressive agents and monitor their 
levels more frequently because of major CYP3A4 and P-glycoprotein drug-drug interactions. 
Formal dosing recommendations and the degree of dose adjustments in HCT recipients are 
conservatively estimated since pharmacokinetic studies have not evaluated dosage changes; 
studies are limited to healthy volunteers or solid organ transplant recipients. 
 
Knowledge gap 
• Studies are needed of potential interactions between DAAs, immunosuppressive agents, and 
chemotherapy used in HCT candidates. 
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Overlap between toxic effects of DAAs and toxic effects of conditioning regimens and 
symptoms of GVHD in HCV-infected HCT candidates and recipients  
S. P. Hammond, S. Giralt 
 
Recommendations 
• No recommendations can be made regarding overlap between the toxic effects of DAAs and 
the toxic effects of HCT conditioning regimens or symptoms of GVHD because evidence is 
lacking. 
 
Evidence summary 
Historically, treatment of HCV with interferon and ribavirin in allogeneic HCT recipients 
was carried out with some trepidation because of concerns about exacerbation of GVHD, 
anemia, and neutropenia. However, a relatively large cohort study showed no overall increase in 
GVHD among allogeneic HCT recipients treated with interferon with or without ribavirin after 
transplant, and there was a trend toward a decrease in the risk of severe liver complications after 
transplant with HCV treatment.65 
Because DAAs have been approved by the FDA for treatment of HCV only since 2011, 
information about the use of these agents in allogeneic HCT candidates and recipients is largely 
anecdotal.1 This paucity of data limits understanding of the overlap between the toxic effects of 
DAAs and the toxic effects of HCT conditioning regimens and symptoms of GVHD. 
The first DAAs approved to treat genotype 1 HCV infection, telaprevir and boceprevir, 
were both associated with toxic effects that could be mistakenly attributed to GVHD (e.g., rash) 
or HCT conditioning regimens (e.g., anemia) in the appropriate clinical context.66,67 However, 
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the availability of potent alternatives with fewer side effects to treat genotype 1 HCV has made 
telaprevir and boceprevir less desirable than other agents (both telaprevir and boceprevir have 
been removed from US market).47,48 Simeprevir, a more recently approved protease inhibitor, 
can cause mild hyperbilirubinemia, which could also be mistakenly attributed to GVHD in the 
appropriate clinical context, but this effect is typically transient.68 
In general, the observed toxic effects of newer DAAs that are approved for clinical use 
outside of clinical trials are minimal compared to the toxic effects of interferon, ribavirin, and 
even telaprevir and boceprevir. Further studies and more postmarketing experience with these 
medications, particularly in patients with hematologic disorders and patients who have 
undergone HCT, will be crucial for predicting potential toxic effects unique to HCT recipients. 
 
Knowledge gap 
• Toxicity profile of DAAs in HCT recipients, including the toxic effects on progenitor cells. 
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Table 1. Grading System Used to Rate the Level of the Evidence and Strength of the 
Recommendation for Each Recommendation 
Recommendations are based on scientific evidence and expert opinion. Each recommended 
statement includes a Roman numeral (I, II, or III) that represents the level of the evidence that 
supports the recommendation, and a letter (A, B, or C) that represents the strength of the 
recommendation. 
 
Classification Description 
Class I Conditions for which there is evidence and/or general agreement that a 
given diagnostic evaluation, procedure, or treatment is beneficial, 
useful, and effective 
Class II Conditions for which there is conflicting evidence and/or a divergence 
of opinion about the usefulness and efficacy of a diagnostic evaluation, 
procedure, or treatment 
Class IIa Weight of evidence and/or opinion is in favor of usefulness and 
efficacy 
Class IIb Usefulness and efficacy are less well established by evidence and/or 
opinion 
Class III Conditions for which there is evidence and/or general agreement that a 
diagnostic evaluation, procedure, or treatment is not useful and 
effective or if it in some cases may be harmful 
Level of Evidence Description 
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Adapted from the American College of Cardiology and the American Heart Association Practice 
Guidelines. (American Heart Association, 2011); (Shiffman, 2003) 
*In some situations, such as for IFN-sparing HCV treatments, randomized clinical trials with an 
existing standard-of-care arm cannot ethically or practicably be conducted.  The FDA has 
suggested alternative study designs, including historical controls or immediate versus deferred, 
placebo-controlled trials. For additional examples and definitions see FDA link: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U
CM225333.pdf.  In those instances for which there was a single pre-determined, FDA-approved 
equivalency established, panel members considered the evidence as equivalent to a randomized 
controlled trial for levels A or B.  
Level A* Data derived from multiple randomized clinical trials, meta-analyses, 
or equivalent 
Level B* Data derived from a single randomized trial, nonrandomized studies, 
or equivalent 
Level C Consensus opinion of experts, case studies, or standard of care 
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Table 2. Summary of Changes Compared to the Guidelines Published in 20094 
Major Change Starting Page 
Updated background on natural history of HCV infection in HCT recipients 7 
New recommendations regarding HCV screening 
1) Screening of all hematopoietic cell donors within 30 days before cell harvest with 
FDA-approved HCV antibody and RNA testing in accordance with the FACT 
standards and FDA guidance (class I, level C) 
2) Screening of all long-term survivors of HCT, especially those with epidemiologic 
risk factors including those transplanted in the era before routine donor and blood 
product screening (class I, level C) 
11 
Updated background on impact of HCV infection on eligibility to donate hematopoietic 
cells or undergo HCT 
  14 
(Table 3) 
New section regarding monitoring HCV in chronically infected HCT recipients 
1) ALT level should be evaluated at entry into care, 2 to 8 weeks after completion of 
the conditioning regimen, every 2 to 8 weeks during maintenance chemotherapy 
or immunosuppressive treatment, and every 3 to 6 months thereafter (class II, 
level C)  
2) In HCT recipients with chronic HCV infection, routine monitoring of HCV RNA 
is not recommended. However, viral load should be considered for patients who 
have an unexplained elevation of ALT (class II, level C). HCV RNA should be 
measured in all patients at entry into care, and monitoring of viral load should be 
performed in patients receiving HCV treatment according to the AASLD-IDSA 
17 
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AASLD, American Association for the Study of Liver Diseases; ALT, serum alanine 
aminotransferase; DAAs, direct-acting antiviral agents; FACT, Foundation for the Accreditation 
of Cellular Therapies; FDA, US Food and Drug Administration; HCT, hematopoietic cell 
transplant; HCV, hepatitis C virus; IDSA, Infectious Diseases Society of America. 
HCV guidance (http://www.hcvguidelines.org/) (class I, level C). 
New section regarding  fibrosis assessment in HCV-infected HCT candidates and 
recipients using serologic markers and ultrasound-based vibration-controlled transient 
elastography 
20 
New recommendations regarding antiviral therapy for donors and HCT candidates and 
recipients 
1) Timing of antiviral therapy 
2) Treatment interruption is not recommended (class I, level C) 
3) Interferon-based regimens should be avoided because of their suboptimal efficacy 
and safety (class I, level B) 
4) DAA combinations of potential use in HCV-infected HCT recipients extrapolated 
from studies in other patient populations 
 
 
24 
24 
 
25 
28 
New section and table on drug-drug interactions in HCV-infected HCT candidates and 
recipients receiving DAAs and conditioning regimens or immunosuppressive agents 
31 
Table 4 
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Table 3.  Eligibility to donate hematopoietic stem cells or undergo hematopoietic cell transplant according to different clinical scenarios 
Clinical 
scenario 
Donor  
anti-HCV 
Donor  
HCV RNA 
HCT Candidate/  
Recipient anti-HCV 
HCT candidate/  
recipient HCV RNA 
Recommendation for 
donor 
Recommendation  for HCT 
candidate/  
recipient 
1.  Negative Negative Negative Negative Proceed with stem cell 
harvest. 
Proceed with HCT. 
2.  Negative Positive Negative Negative Proceed with stem cell 
harvest.  When possible, 
start antivirals and proceed 
with cell harvest once HCV 
PCR is undetectable.*  
Proceed with HCT. Monitor 
HCV RNA managing acute 
infection per HCV guidance.†  
3.  Negative Positive Positive Negative Proceed with stem cell 
harvest.  When possible, 
start antivirals and proceed 
with cell harvest once HCV 
PCR is undetectable.* 
Proceed with HCT. Monitor 
HCV RNA managing acute 
infection per HCV guidance.†  
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4.  Negative Positive Positive Positive Proceed with stem cell 
harvest.‡ 
Proceed with HCT.‡ Start 
antiviral therapy, when 
possible.§ 
5.  Negative Positive Negative Positive Proceed with stem cell 
harvest.‡ 
Proceed with HCT.‡ Start 
antiviral therapy, when 
possible.§ 
6.  Negative Negative Positive Negative Proceed with stem cell 
harvest. 
Proceed with HCT.||  
 
7.  Negative Negative Positive Positive Proceed with stem cell 
harvest. 
Proceed with HCT. Start 
antivirals, when possible.§  
8.  Negative Negative Negative Positive Proceed with stem cell 
harvest. 
Proceed with HCT. Start 
antivirals, when possible.§ 
9.  Positive Negative Negative Negative Proceed with stem cell 
harvest.||  
Proceed with HCT. 
10.  Positive Positive Negative Negative Proceed with stem cell 
harvest.  When possible, 
Proceed with HCT. Monitor 
HCV RNA managing acute 
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start antivirals and proceed 
with cell harvest once HCV 
PCR is undetectable.*  
infection per HCV guidance.†  
11.  Positive Positive Positive Negative Proceed with stem cell 
harvest. When possible, 
start antivirals and proceed 
with cell harvest once HCV 
PCR is undetectable.*,||  
Proceed with HCT.†   
Monitor HCV RNA 
managing acute infection per 
HCV guidance.†  
12.  Positive Positive Negative Positive Proceed with stem cell 
harvest.c  Manage infection 
per HCV guidance. 
Proceed with HCT.‡  Start 
antivirals, when possible.§ 
13.  Positive Positive Positive Positive Proceed with stem cell 
harvest.‡ Manage infection 
per HCV guidance. 
Proceed with HCT.‡ Start 
antivirals, when possible.§ 
14.  Positive Negative Positive Positive Proceed with stem cell 
harvest.||  
Proceed with HCT. Start 
antivirals, when possible.§ 
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Anti-HCV, HCV antibody HCT; hematopoietic cell transplant; HCV, hepatitis C virus. 
* When possible, start antiviral therapy immediately attaining viral clearance prior to stem cell harvest to reduce the risk of HCV transmission. If 
HCT must be done urgently, stem cell harvest from a viremic donor should be considered. 
† Per HCV guidance, monitor HCV RNA (e.g., every 4 to 8 weeks) for 6 to 12 months after the time of infection to determine spontaneous viral 
clearance versus active HCV. Detectable HCV RNA at 6 months after onset of infection will identify most persons who need HCV therapy 
(http://hcvguidelines.org/full-report/management-acute-hcv-infection). 
‡ HCV-infected HCT candidates requiring HCT and for whom there is no alternative donor can proceed with HCT from a donor also infected 
with HCV (see text for details). 
15.  Positive Negative Negative Positive Proceed with stem cell 
harvest.||  
Proceed with HCT. Start 
antivirals, when possible.‡,§ 
16.  Positive Negative Positive Negative Proceed with stem cell 
harvest.||  
Proceed with HCT.||  
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§ HCV-infected HCT candidates should be started on therapy and should complete HCV therapy before transplant, when possible. 
|| HCT donors and candidates with positive anti-HCV in the setting of undetectable HCV RNA should have repeat HCV RNA testing when there 
is strong suspicion of acute infection or in patients with ongoing risk factors for HCV infection (see text for details). 
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Table 4.  Direct-Acting Antiviral Agent (DAA) Pharmacology and Potential Interactions with Drugs Used in Hematopoietic 
Cell Transplant (HCT) 
Antiviral Agent* Metabolism/Elimination 
Metabolism 
Effects 
Transporter 
Substrate 
Transporter 
Effects 
Drugs with Which DAA Does 
or May Interact 
Protease inhibitors    
Boceprevir CYP3A4, aldoreductase Inhibits CYP3A4 P-gp Potentially inhibits 
P-gp 
Increase azoles, CSA, 
tacrolimus, sirolimus, etoposide, 
Cy levels 
Paritaprevir (ABT-450) 
with ritonavir† 
CYP3A4, CYP3A5 Inhibits CYP3A4,  
UGT1A1 
ABCG2, 
OATP1B1/3, P-gp 
Inhibits ABCG2, 
OATPB1/3 
Increase azoles, CSA, 
tacrolimus, sirolimus, etoposide, 
Cy levels 
Simeprevir CYP3A4 Inhibits CYP1A2, 
intestinal CYP3A4 
OATP1B1/3, P-gp Inhibits 
OATP1B1/3, P-gp 
Increase azoles, CSA, 
tacrolimus, sirolimus, etoposide, 
Cy levels 
Telaprevir CYP3A4 Inhibits CYP3A4 OATP1B1, 
OATP2B1, P-gp 
Inhibits OATP1B1, 
OATP2B1, P-gp 
Increase azoles, CSA, 
tacrolimus, sirolimus, etoposide, 
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Cy levels 
Ritonavir†  CYP3A4, CYP2D6 Inhibits CYP3A4 P-gp Inhibits ABCG2 Increase azoles, CSA, 
tacrolimus, sirolimus, etoposide, 
Cy levels 
NS5A inhibitor      
Daclatasvir CYP3A4 No data P-gp Inhibitor of 
ABCG2, 
OATP1B1, P-gp 
Increase CSA,  
tacrolimus levels‡ 
Ledipasvir Oxidized by unknown 
mechanisms 
N/A ABCG2, P-gp inhibits ABCG2, P-
gp 
Increase CSA,  
tacrolimus levels 
Ombitasvir (ABT-267) Amide hydrolysis then 
oxidation 
Inhibits UGT1A1 ABCG2, P-gp substrate only Unknown 
Nonnucleos(t)ide 
polymerase inhibitor 
     
Dasabuvir (ABT-333) CYP2C8 (primary), CYP3A4, 
CYP2D6 
Inhibits UGT1A1 ABCG2, P-gp Inhibit ABCG2 CYP2D6 inhibitors increase 
dasabuvir 
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Nucleos(t)ide 
polymerase inhibitor 
     
Sofosbuvir Extensive hepatic metabolism§ 
to active moiety GS-461203, 
then majority is renally 
eliminated 
N/A ABCG2, P-gp substrate only Unknown 
Nucleoside analog      
Ribavirin Unknown metabolism, 60% 
renal elimination 
N/A N/A N/A Increase myelotoxicity with 
azathioprine 
P-gp, P-glycoprotein; OATP1B1/3, organic anion-transporting polypeptides 1B1 and 1B3; OATP2B1, organic anion-transporting 
polypeptides 2B1; ABCG2, ATP-binding cassette sub-family G member 2; CSA, cyclosporine; Cy, cyclophosphamide; N/A, not applicable.  
*Boceprevir and telaprevir are no longer available in the US but still in use in other countries. Ombitasvir, paritaprevir, ritonavir, and 
dasabuvir are co-packaged under the brand name VIEKIRA PAK. Ledipasvir and sofosbuvir are co-packaged under the brand name 
HARVONI. 
†
 Ritonavir is used to boost plasma concentrations of paritaprevir. 
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‡ Based on the results of drug interaction trials, no clinically relevant changes in exposure were observed for cyclosporine or tacrolimus with 
concomitant use of daclatasvir.52 
§
 Metabolic pathway involves hydrolysis of carboxyl ester moiety catalyzed by human cathepsin A or carboxylesterase 1 and 
phosphoramidate cleavage by histidine triad nucleotide-binding protein 1 followed by phosphorylation by the pyrimidine nucleotide 
biosynthesis pathway.   
guide.medlive.cn
